
    
      A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy
      and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with
      chronic low back pain. Subjects will go through an open-label conversion and titration phase
      followed by a randomized double-blind treatment phase of Hydrocodone (HC)-Controlled-Release
      (CR) vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label
      Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase,
      and a 2-week Follow-Up Phone Call
    
  